Novartis News | finanzen.ch

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Strukturierte Produkte

Aktion

Portfolio

Watchlist

16.11.16	Novartis announces AMG 334 significantly reduces monthly migraine days in second pivotal Phase III episodic migraine study (GlobeNewswire)
16.11.16	Novartis data at ASH and SABCS showcase latest innovations in development for patients with blood disorders and breast cancer (GlobeNewswire)
15.11.16	New analysis of Novartis' Entresto® data shows long-term benefits on heart failure readmissions and total cardiovascular deaths (GlobeNewswire)
14.11.16	Novartis drug PKC412 (midostaurin) granted FDA Priority Review for newly-diagnosed FLT3-mutated AML and advanced systemic mastocytosis (GlobeNewswire)
14.11.16	Novartis presents new Cosentyx data showing long-lasting efficacy in psoriatic arthritis over 3 years including patient-reported pain (GlobeNewswire)
14.11.16	Novartis improves ranking in 2016 Access to Medicine Index (GlobeNewswire)
01.11.16	Novartis LEE011 (ribociclib) granted FDA Priority Review for first-line treatment of HR+/HER2- advanced breast cancer (GlobeNewswire)
31.10.16	Novartis Wins Two Prestigious Prix Galien Foundation Awards; Gleevec® recognized as "Discovery of the Decade" for Best Pharmaceutical Product, Cosentyx® as Best Biotechnology Product (GlobeNewswire)
25.10.16	Novartis delivered solid third quarter with Growth Products[1] offsetting Gleevec patent expiration; several positive readouts for potential blockbusters (GlobeNewswire)
25.10.16	Novartis erzielt im dritten Quartal solide Ergebnisse, wobei die Wachstumsprodukte[1] den Verlust des Patents für Gleevec wettmachen; mehrere positive Daten für potenzielle Blockbuster (GlobeNewswire)
17.10.16	Alcon launches the CyPass® Micro-Stent at the American Academy of Ophthalmology (AAO) 2016 annual meeting (GlobeNewswire)
09.10.16	Novartis ALK+ metastatic NSCLC therapy Zykadia® extends progression-free survival beyond 18 months in Phase II study (GlobeNewswire)
08.10.16	Novartis' Tafinlar® (dabrafenib) + Mekinist® (trametinib) demonstrate superior overall survival benefit in advanced melanoma patients at three-year follow up (GlobeNewswire)
08.10.16	Novartis breakthrough therapy LEE011 plus letrozole demonstrates superior progression-free survival as first-line treatment for HR+/HER2- advanced breast cancer compared to a standard of care (GlobeNewswire)
03.10.16	Novartis reports over half of psoriasis patients do not reach the achievable treatment goal of clear skin in largest global survey (GlobeNewswire)
01.10.16	Novartis late-breaking data show Cosentyx delivers high and long-lasting skin clearance over 4 years for psoriasis patients (GlobeNewswire)
28.09.16	Novartis announces Phase III study shows AMG 334 significantly reduces monthly migraine days in people with episodic migraine (GlobeNewswire)
28.09.16	Sandoz invites young entrepreneurs to enter Sandoz HACk, a global competition to help solve healthcare access challenges (GlobeNewswire)
23.09.16	Novartis receives three new FDA approvals for the expanded use of Ilaris treating rare Periodic Fever Syndrome conditions (GlobeNewswire)
23.09.16	Novartis announces positive top-line results from ASCEND-4, a Phase III trial of Zykadia® in untreated adult ALK+ NSCLC patients (GlobeNewswire)
21.09.16	Novel Novartis malaria compound shows potential to be effective against infections resistant to all currently available antimalarial drugs (GlobeNewswire)
19.09.16	Important new analysis shows that Novartis' Entresto® is associated with higher relative health-related quality of life scores among HFrEF patients (GlobeNewswire)
17.09.16	Novartis BAF312 reduces the risk of disability progression in pivotal phase III study in secondary progressive MS patients (GlobeNewswire)
16.09.16	New Novartis data presented at ECTRIMS show benefit of Gilenya® on patient disability progression at 10 years (GlobeNewswire)
15.09.16	Novartis presents new positive data at EHMTIC showing AMG 334 significantly reduces monthly migraine days in chronic migraine (GlobeNewswire)
15.09.16	Novartis Foundation showcases progress in leprosy elimination programs at 19th International Leprosy Congress (GlobeNewswire)
09.09.16	New Novartis point of care Niji(TM) System may provide earlier diagnosis of severe allergic asthma and faster treatment decisions (GlobeNewswire)
08.09.16	Alcon launches the NGENUITY® 3D Visualization System designed to further enhance retinal surgeon experience (GlobeNewswire)
03.09.16	Novartis' Ultibro® Breezhaler® consistently more effective than Seretide®* in reducing COPD flare-ups across different patient groups (GlobeNewswire)
31.08.16	AirFluSal® Forspiro® showed superiority at 12 months over Seretide® Diskus®[1] in persistence to treatment (GlobeNewswire)
30.08.16	FDA approves Sandoz Erelzi(TM) to treat multiple inflammatory diseases (GlobeNewswire)
29.08.16	Novartis convenes experts to discuss new technologies in healthcare at Novartis International BioCamp (GlobeNewswire)
29.08.16	Experten diskutieren am Novartis International BioCamp neue Technologien im Gesundheitsbereich (GlobeNewswire)
25.08.16	Novartis announces positive phase III results showing efficacy of BAF312 in patients with secondary progressive MS (GlobeNewswire)
15.08.16	Six leading scientists to receive prestigious Novartis Prizes for Immunology at 16th International Congress of Immunology (GlobeNewswire)
03.08.16	Novartis CDK4/6 inhibitor LEE011 (ribociclib) receives FDA Breakthrough Therapy designation as first-line treatment for HR+/HER2- advanced breast cancer (GlobeNewswire)
02.08.16	Alcon achieves US approval for CyPass® Micro-Stent, a micro invasive surgical device to treat glaucoma (GlobeNewswire)
19.07.16	Novartis delivered solid Q2 despite full quarter of US Gleevec generic impact; significant positive innovation news strengthens future growth prospects (GlobeNewswire)
19.07.16	Novartis erzielt im 2. Quartal solide Ergebnisse trotz US-Generikakonkurrenz für Gleevec im gesamten Quartal; wichtige positive Neuigkeiten zu Innovationen stärken zukünftige Wachstumsperspektiven (GlobeNewswire)
14.07.16	Alcon launches Dailies Total1® Multifocal contact lenses, the first and only water gradient lenses designed for people with presbyopia (GlobeNewswire)
13.07.16	Sandoz biosimilar etanercept recommended by FDA advisory committee for approval to treat multiple inflammatory diseases (GlobeNewswire)
07.07.16	New data shows Sandoz biosimilar etanercept candidate has equivalent efficacy to originator product (GlobeNewswire)
29.06.16	Novartis PKC412 (midostaurin) pivotal data published in NEJM show 60% response rate in advanced systemic mastocytosis (SM) (GlobeNewswire)
29.06.16	Largest global psoriasis survey shows 84% of people face discrimination and humiliation because of their skin (GlobeNewswire)
28.06.16	Novartis adds bispecific antibodies to its growing immuno-oncology portfolio through collaboration and licensing agreement with Xencor (GlobeNewswire)
22.06.16	Timely use of Novartis' Entresto could prevent or postpone over 28,000 US deaths per year among HFrEF patients, according to an expert analysis in JAMA Cardiology (GlobeNewswire)
15.06.16	Novartis erweitert Partnerschaft mit Medicines for Malaria Venture zur Entwicklung von Malariamedikamenten der nächsten Generation (GlobeNewswire)
15.06.16	Novartis expands partnership with Medicines for Malaria Venture to develop next-generation antimalarial treatment (GlobeNewswire)
10.06.16	Novartis highlights long-term safety data of Revolade® in adults with chronic immune thrombocytopenia, a rare blood disorder (GlobeNewswire)
10.06.16	Novartis presents data showing Jakavi® is superior to best available therapy in patients with less advanced polycythemia vera (PV) (GlobeNewswire)

Newssuche

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

UBS Group	28.29	2.02 %	K V
Swiss Life Hldg	706.60	1.00 %	K V
Swiss Re	132.50	0.99 %	K V
Zurich Insur Gr	542.60	0.71 %	K V
Roche Hldg G	257.10	0.63 %	K V
Geberit	512.40	-0.43 %	K V
Nestle	74.52	-0.48 %	K V
Alcon	76.32	-0.75 %	K V
CieFinRichemont	136.50	-1.02 %	K V
Logitech Intl	74.18	-1.15 %	K V

mehr

09:28		Schwache Performance in Frankfurt: TecDAX verbucht zum Handelsstart Verluste
09:28		Börse Europa in Rot: STOXX 50 beginnt Freitagshandel in der Verlustzone
09:28		Freundlicher Handel: LUS-DAX zum Start im Plus
09:28		Börse Frankfurt in Rot: DAX beginnt die Sitzung weit in der Verlustzone
09:28		Freundlicher Handel: SPI zum Handelsstart auf grünem Terrain
09:28		Handel in Frankfurt: MDAX verbucht zum Start Verluste
09:28		Starker Wochentag in London: FTSE 100 zum Handelsstart in der Gewinnzone